Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Phase III Randomized Open Label Study to Compare NKTR-214
Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma (PSCI 18-122)
The purpose of the study is to compare how well the drug called NKTR-214 works when combined with the other drugs: nivolumab, sunitinib, and cabozantinib in patients with renal cell carcinoma.
18 years or older Karnofsky Performance Status of at least 70 advanced or metastatic renal carcinoma No prior systemic therapy No active brain metastases
Exclusion Criteria:
Use of an investigational agent or an investigational device within 28 days of randomization autoimmune disease History of organ or tissue transplant Prior major surgery or radiotherapy within 14 days Any tumor invading the major blood vessels